Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Vidal

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Orthodontics & Craniofacial Research|February 9, 2023
Polymorphisms in hormonal-related genes might be associated with variations in permanent tooth crown sizeJennifer Tsi Gerber, Suyany Gabriely Weiss, Laura Vidal Mijolaro, et al.
Head & Neck|March 25, 2009
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinibLaura Vidal, Ming S Tsao, Gregory R Pond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsTimothy A Yap, Laura Vidal, Jan Adam, et al.
Chirurgia (Bucharest, Romania : 1990)|February 27, 2021
Robotic Revisional Experience. Single Centre Prospective Cohort Study and Review of the LiteratureRamon Vilallonga, Arturo Cirera de Tudela, Elsa García Möller, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumoursLaura Vidal, Ivan Victoria, Lydia Gaba, et al.
BMJ Open|April 16, 2026
Indocyanine green fluorescence for intraoperative detection of liver tumours in minimally invasive surgery: protocol for the LIVERGREEN phase IV multicentre clinical trialMartín Huerta, Santiago Lopez-Ben, Laura Lladó, et al.
Neuroepidemiology|August 7, 2025
TRENDS IN HOSPITAL DISCHARGES WITH PRIMARY DIAGNOSIS OF CEREBRAL VENOUS THROMBOSIS BY AGE AND SEX IN SPAINEduardo Mariño, Sofía Ramírez-Guerrero, Jorge Rodríguez-Pardo, et al.
Bioorganic & Medicinal Chemistry Letters|December 2, 2014
Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists IJuan Antonio Alonso, Miriam Andrés, Mónica Bravo, et al.
Bioorganic & Medicinal Chemistry Letters|December 2, 2014
Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists II: lead optimizationJuan Antonio Alonso, Miriam Andrés, Mónica Bravo, et al.
The Pharmacogenomics Journal|March 10, 2018
Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritisRosario López-Rodríguez, Aida Ferreiro-Iglesias, Aurea Lima, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Orthodontics & Craniofacial Research|February 9, 2023
Polymorphisms in hormonal-related genes might be associated with variations in permanent tooth crown sizeJennifer Tsi Gerber, Suyany Gabriely Weiss, Laura Vidal Mijolaro, et al.
Head & Neck|March 25, 2009
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinibLaura Vidal, Ming S Tsao, Gregory R Pond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsTimothy A Yap, Laura Vidal, Jan Adam, et al.
Chirurgia (Bucharest, Romania : 1990)|February 27, 2021
Robotic Revisional Experience. Single Centre Prospective Cohort Study and Review of the LiteratureRamon Vilallonga, Arturo Cirera de Tudela, Elsa García Möller, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumoursLaura Vidal, Ivan Victoria, Lydia Gaba, et al.
BMJ Open|April 16, 2026
Indocyanine green fluorescence for intraoperative detection of liver tumours in minimally invasive surgery: protocol for the LIVERGREEN phase IV multicentre clinical trialMartín Huerta, Santiago Lopez-Ben, Laura Lladó, et al.
Neuroepidemiology|August 7, 2025
TRENDS IN HOSPITAL DISCHARGES WITH PRIMARY DIAGNOSIS OF CEREBRAL VENOUS THROMBOSIS BY AGE AND SEX IN SPAINEduardo Mariño, Sofía Ramírez-Guerrero, Jorge Rodríguez-Pardo, et al.
Bioorganic & Medicinal Chemistry Letters|December 2, 2014
Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists IJuan Antonio Alonso, Miriam Andrés, Mónica Bravo, et al.
Bioorganic & Medicinal Chemistry Letters|December 2, 2014
Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists II: lead optimizationJuan Antonio Alonso, Miriam Andrés, Mónica Bravo, et al.
The Pharmacogenomics Journal|March 10, 2018
Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritisRosario López-Rodríguez, Aida Ferreiro-Iglesias, Aurea Lima, et al.
Pageof 13